Relative Selectivity of Covalent Inhibitors Requires Assessment of Inactivation Kinetics and Cellular Occupancy: A Case Study of Ibrutinib and Acalabrutinib

Full article: Drug delivery targets and strategies to address mast cell diseases

A guide to enzyme kinetics in early drug discovery - Srinivasan - 2023 - The FEBS Journal - Wiley Online Library

Tyrosine Kinase: Most Up-to-Date Encyclopedia, News & Reviews

Covalent Modifiers: 2017

Case Study - COVALfinder to Study Irreversible EGFR Drugs

Advances in covalent drug discovery

Melissa Hopper - Immunology Doctoral Candidate - Mayo Clinic Graduate School of Biomedical Sciences

A road map to evaluate the proteome-wide selectivity of covalent kinase inhibitors

A steady-state algebraic model for the time course of covalent enzyme inhibition

Ibrutinib Inhibits Platelet Integrin αIIbβ3 Outside-In Signaling and Thrombus Stability But Not Adhesion to Collagen

Kinetic mechanisms of covalent inhibition - ScienceDirect

Selective Inhibition of Bruton's Tyrosine Kinase by a Designed Covalent Ligand Leads to Potent Therapeutic Efficacy in Blood Cancers Relative to Clinically Used Inhibitors